11.27
1.08%
0.12
Pre-market:
11.04
-0.23
-2.04%
Roivant Sciences Ltd stock is traded at $11.27, with a volume of 4.25M.
It is up +1.08% in the last 24 hours and down -2.59% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$11.15
Open:
$11.22
24h Volume:
4.25M
Relative Volume:
0.94
Market Cap:
$8.20B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
1.9947
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
+3.02%
1M Performance:
-2.59%
6M Performance:
+2.45%
1Y Performance:
+8.89%
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
Compare ROIV with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
11.27 | 8.20B | 125.68M | 4.81B | -781.21M | 5.65 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-15-24 | Initiated | Wolfe Research | Outperform |
Jan-05-24 | Initiated | Piper Sandler | Overweight |
Dec-12-23 | Initiated | Deutsche Bank | Buy |
Oct-17-23 | Initiated | Guggenheim | Buy |
Jun-08-23 | Initiated | BofA Securities | Neutral |
Oct-27-22 | Initiated | JP Morgan | Overweight |
May-23-22 | Initiated | SVB Leerink | Outperform |
Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
Dec-15-21 | Initiated | Goldman | Buy |
Nov-08-21 | Initiated | H.C. Wainwright | Buy |
Oct-28-21 | Initiated | Citigroup | Buy |
Oct-26-21 | Initiated | Cowen | Outperform |
Oct-26-21 | Initiated | Jefferies | Buy |
Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
What Is Vivek Ramaswamy’s net worth? The Indian American man who took on Trump and then became a confidante - The Financial Express
Trump Inauguration: Who Is Vivek Ramaswamy and what’s his role in Trump 2.0? - The Financial Express
Roivant Sciences Sees Unusually High Options Volume (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Ltd. Trade Ideas — LS:A3C4MS - TradingView
Roivant Sciences Ltd. (NASDAQ:ROIV) Director Acquires $336,900,200.00 in Stock - MarketBeat
Roivant sciences increases stake in Immunovant with $336.9 million purchase By Investing.com - Investing.com Nigeria
Roivant sciences increases stake in Immunovant with $336.9 million purchase - Investing.com
Is Roivant Sciences (ROIV) the Best Medical Stock to Buy Under $20? - Insider Monkey
12 Best Medical Stocks To Buy Under $20 - Insider Monkey
Nordea Investment Management AB Raises Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
ROIVWroivw Latest Stock News & Market Updates - StockTitan
ROIV Crosses Below Key Moving Average Level - Nasdaq
Arbutus could benefit from Big Pharma bird flu vaccines: Jefferies - MSN
Why Ramaswamy Says America Needs a Cultural Shift Towards Excellence for the Sake of US Students - The Times of India
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $17.93 Consensus Target Price from Analysts - MarketBeat
Why Roivant Sciences Ltd. (ROIV) Is Skyrocketing - Yahoo Finance
10 Firms End 2024 Stronger With Impressive Gains - Insider Monkey
Strategic Sale: Eric Venker Decides To Exercise Options Worth $3.86M At Roivant Sciences - Benzinga
Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $2,050,704.16 in Stock - MarketBeat
Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 176,900 Shares of Stock - MarketBeat
Roivant Sciences' president sells common shares worth $4.1 million - Investing.com India
Principal Financial Group Inc. Has $11.65 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences' CIO Mayukh Sukhatme sells $10.6m in shares - Investing.com India
Eric Venker Sells 100,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat
Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CIO Sells 689,495 Shares of Stock - MarketBeat
Mayukh Sukhatme Sells 185,946 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat
Roivant sciences president Eric Venker sells $1.15 million in shares By Investing.com - Investing.com Nigeria
Roivant Sciences’ CIO Mayukh Sukhatme sells $10.6m in shares By Investing.com - Investing.com Nigeria
Roivant Sciences' CIO Mayukh Sukhatme sells $10.6m in shares By Investing.com - Investing.com South Africa
Roivant sciences president Eric Venker sells $1.15 million in shares - Investing.com
Barclays PLC Buys 75,609 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Mayukh Sukhatme Sells 412,584 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat
Roivant sciences executive sells common shares worth $4.97 million - Investing.com India
Geode Capital Management LLC Acquires 1,460,205 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Retirement Systems of Alabama Buys 112,286 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Ramaswamy Urges BuzzFeed to Cut Jobs, Air More Conservative Voices - MSN
Trump administration will have financial ties to biotechs - BioCentury
State Street Corp Buys 1,118,561 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
What is Leerink Partnrs' Estimate for ROIV Q3 Earnings? - MarketBeat
Several Positive Developments Lifted Roivant (ROIV) in Q3 - Insider Monkey
Edgestream Partners L.P. Buys Shares of 48,226 Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):